Compare NRDY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | CRDF |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.9M | 130.7M |
| IPO Year | 2020 | 2012 |
| Metric | NRDY | CRDF |
|---|---|---|
| Price | $0.81 | $1.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.00 | ★ $9.63 |
| AVG Volume (30 Days) | ★ 838.7K | 663.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.16 | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $6.08 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.77 | $1.48 |
| 52 Week High | $1.90 | $4.56 |
| Indicator | NRDY | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 32.60 | 44.22 |
| Support Level | $0.80 | $1.51 |
| Resistance Level | $0.99 | $2.05 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 2.16 | 1.96 |
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.